Clough Capital Partners L P Invests $856,000 in Denali Therapeutics Inc. $DNLI

Clough Capital Partners L P acquired a new position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 51,830 shares of the company’s stock, valued at approximately $856,000.

Other hedge funds also recently modified their holdings of the company. Headlands Technologies LLC acquired a new stake in shares of Denali Therapeutics during the second quarter worth approximately $26,000. Johnson Financial Group Inc. acquired a new stake in shares of Denali Therapeutics during the third quarter worth approximately $29,000. State of Wyoming acquired a new stake in shares of Denali Therapeutics during the second quarter worth approximately $29,000. Aster Capital Management DIFC Ltd acquired a new stake in shares of Denali Therapeutics during the fourth quarter worth approximately $57,000. Finally, Quarry LP acquired a new stake in shares of Denali Therapeutics during the third quarter worth approximately $64,000. Institutional investors and hedge funds own 92.92% of the company’s stock.

Denali Therapeutics Stock Performance

Shares of Denali Therapeutics stock opened at $23.49 on Thursday. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.28 and a quick ratio of 9.28. The firm has a market cap of $3.73 billion, a P/E ratio of -8.16 and a beta of 1.03. The firm has a 50 day simple moving average of $19.94 and a 200 day simple moving average of $19.52. Denali Therapeutics Inc. has a fifty-two week low of $12.58 and a fifty-two week high of $24.21.

Denali Therapeutics (NASDAQ:DNLI) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.69) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.04. During the same quarter last year, the business posted ($0.78) earnings per share. Sell-side analysts predict that Denali Therapeutics Inc. will post -2.77 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently weighed in on DNLI shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Denali Therapeutics in a report on Monday, April 20th. Wolfe Research assumed coverage on shares of Denali Therapeutics in a report on Monday, February 23rd. They issued a “peer perform” rating for the company. The Goldman Sachs Group raised their price target on shares of Denali Therapeutics from $35.00 to $40.00 and gave the company a “buy” rating in a report on Thursday, March 26th. Deutsche Bank Aktiengesellschaft set a $31.00 price target on shares of Denali Therapeutics in a report on Friday, May 22nd. Finally, Wall Street Zen raised shares of Denali Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, May 9th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Denali Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $34.25.

Denali Therapeutics Company Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.